Q3 2024 Procept Biorobotics Corp Earnings Call Transcript
Key Points
- PROCEPT BioRobotics Corp (PRCT) reported a strong financial performance with a 66% revenue growth in Q3 2024 compared to Q3 2023.
- The company achieved a record gross margin of 63.2%, indicating strong operational efficiency.
- International revenue grew by 86%, driven by strong sales momentum in the United Kingdom.
- The launch of the new Hydro robotic system was well-received, with positive feedback on its AI features and improved user interface.
- The FDA granted breakthrough device designation for a new clinical study on prostate cancer, potentially expanding the market for PROCEPT BioRobotics Corp (PRCT).
- The launch of the Hydro system posed challenges, including the need for extensive training of sales representatives, which temporarily impacted sales coverage.
- There were macroeconomic factors such as hurricanes and saline shortages that affected procedure volumes.
- The Hydro system is currently 10% more costly to manufacture than the previous AquaBeam system, although this is expected to improve with scale.
- There are ongoing Medicare audits and some payer restrictions that could impact reimbursement dynamics.
- The company is not yet profitable, with a net loss of $21 million reported for Q3 2024, although there is a clear pathway to profitability.
Good morning and welcome to process by robotics third quarter, 2024 earnings conference call. At this time, all participants on a listen-only mode, we will be facilitating a question and answer session towards the end of today's call. As a reminder, this call is being recorded for replay purposes. I would not like to send the call over to Matt BXO, Vice President of Investigations for a few introductory comments.
Good morning and thank you for joining Procept by robotics third quarter, 2024 earnings conference call presenting on today's call are Resis A no Chief Executive Officer, Kevin Waters, Chief Financial Officer and Shamshi Black, Chief Commercial Officer. Before we begin, I'd like to remind listeners that statements made on this conference call that relate to future plans, events or performance are forward-looking statements as defined under the under the Private Securities Litigation Reform Act of 1,995. All these forward-looking statements are based on management's current expectations and beliefs.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
